Half Year 2024 Genscript Biotech Corp Earnings Call Transcript
Key Points
- Genscript Biotech Corp (GNNSF) reported a strong top-line growth with a 43.5% increase in gross revenue, reaching approximately USD 561.4 million.
- The company significantly narrowed its adjusted net loss to about USD 79 million, showcasing improved financial performance.
- Genscript Biotech Corp (GNNSF) has strengthened its intellectual property position with over 350 patents and more than 1,000 patents in the application process.
- The Life Science Group achieved a 9.5% growth in external revenue, driven by enhanced synergy between gene synthesis and protein services.
- Legend, a segment of Genscript Biotech Corp (GNNSF), achieved a 156% year-over-year revenue growth, driven by strong demand for CARVYKTI and capacity expansion.
- ProBio, the biologic CDMO segment, experienced a decline in external revenue to USD 37.1 million due to headwinds in the biotech funding environment.
- The adjusted gross profit margin for ProBio dropped significantly due to price erosion and low capacity utilization.
- The geopolitical tensions have impacted the company's business, particularly in the US market, causing a temporary drop in orders.
- Genscript Biotech Corp (GNNSF) took a USD 37 million impairment on long-term assets and a USD 113 million fair value loss from ProBio preferred shares.
- The company faces challenges in maintaining profitability in the ProBio segment due to increased depreciation and operating costs from new capacity expansions.
Good day and thank you for standing by. Welcome to Genscript biotech interim results conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Chief Financial Officer, Shiniu Wei. Please go ahead.
Thank you, operator. Good morning, everyone, and good evening for colleagues joining us from the US. This is Shiniu Wei. Welcome to Genscript's 2024 interim results conference call. Joining me on the call today are Mr. Robin Meng, our Chairman of the Board; Ms. Sherry Shao, rotating CEO; and Dr. Patrick Liu. After the rotating CEO and Chairman of Genscript Biotech, we also have other senior executives from the business participating.
Before we begin, I'd like to remind everyone about the forward-looking statements we will be making at this time call. Actual results may differ materially from those indicated by such forward-looking statements because of various important
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
